Effective March 17, 2025, The U.S. subsidiary of BeiGene, Ltd. has changed its name to BeOne Medicines USA, Inc. This change comes ahead of our anticipated global rebranding to BeOne Medicines Ltd. and redomiciliation to Switzerland, pending shareholder approval. The new name reflects our commitment to develop innovative medicines and partner with the global community to help as many patients with cancer as possible. To learn more about BeOne Medicines, please follow our new LinkedIn profile @BeOne Medicines.
We're tracking BeiGene's market expansion
New Hiring activity — 1 fresh signal just appeared.
How BeiGene's international expansion compares to its competitors
BeiGeneYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 BeiGeneYou | 0 | 0 | — | 0 | 0 |
Customer Service Manager
View postingGeorgia, United States · 7mo ago
Customer Service Manager
View postingFlorida, United States · 7mo ago
Customer Service Manager
View postingTexas, United States · 7mo ago
No active campaigns
Sign up to track this company and get alerted the moment something changes.
BeiGene's tislelizumab shows significant overall survival benefit in NSCLC trials RATIONALE-315 and RATIONALE-303, demonstrating efficacy in neoadjuvant/adjuvant and late-stage treatment settings.
XtalPi hosted the 2026 Molecular Glue Drug Development Symposium in Shanghai, gathering experts to discuss advancements in molecular glue drug research and development.
BioAQ 2026 summit in Shanghai focuses on biopharmaceutical analysis and quality control, featuring experts from top pharma companies and regulatory bodies.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about BeiGene's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
